Shots:
- Sanofi has reported data from the ongoing P-II (ALPHAMEDIX-02) trial assessing AlphaMedix (67.6μCi/kg, Q8W, ~4 cycles) in pts, incl. PRRT-naïve (n=35) & exposed (n=26) pts with histologically confirmed unresectable or metastatic SSTR+ GEP-NETs & ≥1 site of measurable disease
- Trial met all 1EPs with improved ORR & prolonged benefit, plus showed improvement across 2EPs of PFS & OS in both PRRT-naïve & exposed pts; data to be presented at ESMO’25 & form basis of discussions with health authorities
- AlphaMedix (²¹²Pb-DOTAMTATE), a somatostatin receptor–targeted alpha therapy using lead-212 isotope, received BTD in Feb 2024 for PRRT-naïve pts with unresectable or metastatic, progressive SSTR-expressing GEP-NETs
Ref: Sanofi | Image: Sanofi | Press Release
Related News:- Sanofi Reports P-IIa (HS-OBTAIN) Trial Data of Brivekimig for Hidradenitis Suppurativa
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
